Evidence map›Paper›PMID 31754120›Full record

ArticleScientific reports2019

Treatment with etanercept and low monocyte concentration contribute to the risk of invasive aspergillosis in patients post allogeneic stem cell transplantation.

Tamara Zoran, Michael Weber, Jan Springer, P Lewis White, Joachim Bauer, Annika Schober, Claudia Löffler, Bastian Seelbinder, Kerstin Hünniger, Oliver Kurzai and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

Tamara ZoranUniversity Hospital Würzburg, Medical Hospital II, WÜ4i, Würzburg, Germany.
Michael WeberFriedrich Löffler Institute, Institute of Molecular Pathogenesis, Jena, Germany.
Jan SpringerUniversity Hospital Würzburg, Medical Hospital II, WÜ4i, Würzburg, Germany.
P Lewis WhitePublic Health Wales, Microbiology, Cardiff, UK.
Joachim BauerUniversity Hospital Würzburg, Medical Hospital II, WÜ4i, Würzburg, Germany.
Annika SchoberUniversity Hospital Würzburg, Medical Hospital II, WÜ4i, Würzburg, Germany.
Claudia LöfflerUniversity Hospital Würzburg, Medical Hospital II, WÜ4i, Würzburg, Germany.
Bastian SeelbinderLeibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
Kerstin HünnigerSeptomics Research Centre, Friedrich Schiller University and Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
Oliver KurzaiSeptomics Research Centre, Friedrich Schiller University and Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
André ScheragInstitute of Medical Statistics, Computer and Data Sciences, University Hospital, Jena, Germany.ORCID http://orcid.org/0000-0002-9406-4704
Sascha SchäubleLeibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.ORCID http://orcid.org/0000-0003-3862-6546
C Oliver MortonWestern Sydney University, School of Science and Health, Campbelltown, NSW, 2560, Australia.
Hermann EinseleUniversity Hospital Würzburg, Medical Hospital II, WÜ4i, Würzburg, Germany.
Jörg LindeLeibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
Jürgen LöfflerUniversity Hospital Würzburg, Medical Hospital II, WÜ4i, Würzburg, Germany. Loeffler_j@ukw.de.
Universitätsklinikum Würzburg · DEFriedrich-Loeffler-Institut · DELeibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) · DEUniversity of Würzburg · DECamden and Campbelltown Hospitals · AUJena University Hospital · DEPublic Health Wales · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive aspergillosis (IA) is a life-threatening complication among allogeneic hematopoietic stem cell transplant (alloSCT) recipients. Despite well known risk factors and different available assays, diagnosis of invasive aspergillosis remains challenging. 103 clinical variables from patients with hematological malignancies and subsequent alloSCT were collected. Associations between collected variables and patients with (n = 36) and without IA (n = 36) were investigated by applying univariate and multivariable logistic regression. The predictive power of the final model was tested in an independent patient cohort (23 IA cases and 25 control patients). Findings were investigated further by in vitro studies, which analysed the effect of etanercept on A. fumigatus-stimulated macrophages at the gene expression and cytokine secretion. Additionally, the release of C-X-C motif chemokine ligand 10 (CXCL10) in patient sera was studied. Low monocyte concentration (p = 4.8 × 10

Indexed as

AdultAgedAspergillosisCohort StudiesCytokinesEtanerceptFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansInvasive Fungal InfectionsMaleMiddle AgedMonocytesRisk FactorsTransplantation, HomologousCytokinesEtanercept

Identifiers

PMID31754120
PMCPMC6872713
OpenAlexW2990886237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.